Treatment of feline leukemia virus-infected cats with paramunity inducer

Two placebo-controlled double-blind trials were performed to determine the therapeutic efficacy of the paramunity inducer, Baypamun® in feline leukemia virus (FeLV) -infected cats under controlled conditions. In the first study, 120 cats were involved; 60 cats were treated with Baypamun® and 60 with a placebo preparation of virus-free cell culture medium. Dosage and administration of the drug over a 7-week period were performed according to the instructions given by the company. Remission of viremia occurred in 12% and 7% of the cats treated with Baypamun® and placebo, respectively. This difference was not statistically significant. In the second study, 30 naturally infected cats were treated in a placebo-controlled double-blind trial. In total, 20 immunological, clinical, laboratory, and virological parameters were examined. No statistically significant differences could be demonstrated between Baypamun® and placebo application. Therefore, FeLV infection was not influenced by Baypamun® treatment.